# EDGAR Filing Document

**Accession Number:** 0001873091
**File Stem:** 0001415889-25-022522
**Filing Date:** 2025-8
**Character Count:** 9038
**Document Hash:** 5c63a778a5e992538096d3a224dac639
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-022522.hdr.sgml**: 20250820

**ACCESSION NUMBER**: 0001415889-25-022522

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250818

**FILED AS OF DATE**: 20250820

**DATE AS OF CHANGE**: 20250820

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Barnett Valerie
- **CENTRAL INDEX KEY:** 0001873091

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40632
- **FILM NUMBER:** 251237925

**MAIL ADDRESS:**
- **STREET 1:** C/O CYTEK BIOSCIENCES, INC.
- **STREET 2:** 46107 LANDING PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cytek Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001831915
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472547526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** (877) 922-9835

**MAIL ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cytek BioSciences, Inc.
- **DATE OF NAME CHANGE:** 20201110

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Barnett Valerie<br><sub>(Last) (First) (Middle)</sub><br>C/O CYTEK BIOSCIENCES, INC.<br>47215 LAKEVIEW BOULEVARD<br><sub>(Street)</sub><br>FREMONT, CA 94538<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF LEGAL OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Cytek Biosciences, Inc. [ CTKB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-08-18 |  | M |  | 2016 | A | <sup>(1)</sup> | 85689 | D |  |
| Common Stock | 2025-08-18 |  | F |  | 786<sup>(2)</sup> | D | $4.06 | 84903 | D |  |
| Common Stock | 2025-08-18 |  | M |  | 3681 | A | <sup>(1)</sup> | 88584 | D |  |
| Common Stock | 2025-08-18 |  | F |  | 1434<sup>(2)</sup> | D | $4.06 | 87150 | D |  |
| Common Stock | 2025-08-18 |  | M |  | 7735 | A | <sup>(1)</sup> | 94885 | D |  |
| Common Stock | 2025-08-18 |  | F |  | 3000<sup>(2)</sup> | D | $4.06 | 91885 | D |  |
| Common Stock | 2025-08-18 |  | M |  | 10875 | A | <sup>(1)</sup> | 102760 | D |  |
| Common Stock | 2025-08-18 |  | F |  | 3609<sup>(2)</sup> | D | $4.06 | 99151 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2025-08-18 |  | M |  |  | 2016 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 2016 | $0 | 3362 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2025-08-18 |  | M |  |  | 3681 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 3681 | $0 | 23323 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2025-08-18 |  | M |  |  | 7735 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 7735 | $0 | 79932 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2025-08-18 |  | M |  |  | 10875 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 10875 | $0 | 155888 | D |  |

---

### Footnotes:

(1) Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

(2) Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

(3) The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

(4) The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.

(5) The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.

(6) The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.

**Signature:** /s/ Valerie Barnett  
**Date:** 2025-08-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**